Recently, additional new combinations of BRAF and MEK inhibitors were approved for their usage in malignant melanoma, such as the BRAF inhibitor, encorafenib, and MEK inhibitors, cobimetinib, and binimetinib [152,153,154,155]. This evidence concerns the gene MAP2K7 and melanoma.